SCHEMBL3202915

SCHEMBL3202915

CNC(=O)C(O)C(c1ccccc1)N(C)c1ccc(OC)cc1

nearest known ligand 0.64

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 10/20 0.64
SLC6A4 P31645 10/20 0.64
NPY5R Q15761 1/20 0.50
ACP3 P15309 1/20 0.43
KLK7 P49862 2/20 0.43
HTT P42858 1/20 0.42
NPC1 O15118 1/20 0.42
TP53 P04637 1/20 0.42
MAPT P10636 1/20 0.42
RAB9A P51151 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
ESR2 Q92731 1/20 0.42
NOX1 Q9Y5S8 1/20 0.42
CNR1 P21554 1/20 0.41
CNR2 P34972 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
ALDH1A1 P00352 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
ROCK2 O75116 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3210232 0.95 SLC6A2 (0.64) SLC6A2SLC6A4NPY5RACP3KLK7
SCHEMBL3200042 0.93 SLC6A2 (0.54) SLC6A2SLC6A4NPY5RHTTNPC1
SCHEMBL3201198 0.88 SLC6A2 (0.57) SLC6A2SLC6A4
SCHEMBL3201209 0.88 SLC6A2 (0.57) SLC6A2SLC6A4
SCHEMBL3197836 0.88 SLC6A2 (0.49) SLC6A2SLC6A4KLK7CNR2ALDH1A1
SCHEMBL3199701 0.87 SLC6A2 (0.62) SLC6A2SLC6A4NPY5RACP3TDP1
SCHEMBL3200026 0.86 SLC6A2 (0.66) SLC6A2SLC6A4NPY5RTDP1ALDH1A1
SCHEMBL3191686 0.85 SLC6A2 (0.61) SLC6A2SLC6A4TP53MAPTALDH1A1
SCHEMBL3202079 0.84 SLC6A2 (0.62) SLC6A2SLC6A4NPY5RNPC1MAPT
SCHEMBL3201828 0.84 SLC6A2 (0.62) SLC6A2SLC6A4KLK7NPC1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7671238-B2 Arylamino-arylpropanolamine derivatives and methods of their use WYETH LLC (US) 2010-03-02 US disclosed
WO-2008042362-A1 ARYLAMINO-ARYLPROPANOLAMINE DERIVATIVES AND METHODS OF THEIR USE WYETH (US) 2008-04-10 WO disclosed
US-20080085938-A1 Arylamino-Arylpropanolamine Derivatives and Methods of Their Use WYETH (US) 2008-04-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080085938-A1 Arylamino-Arylpropanolamine Derivatives and Methods of Their Use PNMT, PAH, SLC18A2 SLC6A2 4/4885SLC6A4 6/4885NPY5R 231/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.